deltatrials
Terminated PHASE2 NCT00101075

Title XELOX FOR SALIVARY GLAND CANCERS

Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers

Sponsor: Dana-Farber Cancer Institute

Conditions Head and Neck Cancer
Interventions Capecitabine Oxaliplatin
Updated 6 times since 2017 Last updated: Feb 24, 2017 Started: Oct 31, 2004 Primary completion: Mar 31, 2007 Completion: Mar 31, 2008

Listed as NCT00101075, this PHASE2 trial focuses on Head and Neck Cancer and remains terminated or withdrawn. Sponsored by Dana-Farber Cancer Institute, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Mar 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

▶ Show 1 earlier version

  1. Jan 2017 — Mar 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • National Cancer Institute (NCI)
  • Sanofi-Synthelabo
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States